Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Jeffrey A. Bluestone Joins Gilead Sciences' Board of Directors

Business Wire December 8, 2020

Matinas BioPharma Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead's Antiviral Remdesivir Utilizing Matinas' LNC Platform Delivery Technology

GlobeNewswire December 7, 2020

Yescarta® Shows Positive Results as a First-Line Treatment for Patients With High-Risk Large B-cell Lymphoma

Business Wire December 6, 2020

Magrolimab Demonstrates Clinical Responses in Ongoing Phase 1b Trial of Previously Untreated Acute Myeloid Leukemia Patients

Business Wire December 6, 2020

Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates and Durable Clinical Benefit in a Pivotal Indolent Non-Hodgkin Lymphoma Study

Business Wire December 5, 2020

New Data for TecartusTM Demonstrate Durable Responses at One Year Follow-Up in Relapsed or Refractory Mantle Cell Lymphoma

Business Wire December 5, 2020

New Four-Year Data Show Long-Term Survival in Patients With Large B-Cell Lymphoma Treated With Yescarta® in ZUMA-1 Trial

Business Wire December 5, 2020

Gilead Canada Announces Notice of Compliance for DESCOVY® (emtricitabine, tenofovir alafenamide) for HIV Pre-exposure Prophylaxis (PrEP)

Canada NewsWire December 1, 2020

Gilead Sciences to Present at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020

Business Wire November 23, 2020

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Business Wire November 18, 2020

Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

Business Wire November 15, 2020

Gilead and Kite to Share Latest Scientific Advances in Hematologic Malignancies at ASH 2020

Business Wire November 5, 2020

European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis

Business Wire November 2, 2020

Gilead Sciences Announces Fourth Quarter 2020 Dividend

Business Wire October 28, 2020

Gilead Sciences Announces Third Quarter 2020 Financial Results

Business Wire October 28, 2020

Stocks Dawdle as Investors Keep Eye on Stimulus Talks

Livemoney October 23, 2020

Gilead Sciences Completes Acquisition of Immunomedics, Inc.

Business Wire October 23, 2020

U.S. Food and Drug Administration Approves Gilead's Antiviral Veklury® (remdesivir) for Treatment of COVID-19

Business Wire October 22, 2020

Anthony Welters Joins Gilead Sciences' Board of Directors

Business Wire October 22, 2020

Gilead Announces New Data on Biktarvy® for the Treatment of HIV in Black Americans

Business Wire October 21, 2020